Uveal melanoma dormancy:  an acceptable clinical endpoint?
Uveal melanoma is a rare but life-threatening malignancy. Over the past decades, the morbidity of uveal melanoma has been markedly reduced as a result of advances in the diagnostic ability to detect smaller tumors at an earlier stage. This has allowed for the use of more conservative treatments, avoiding enucleation. Mortality, however, has remained unchanged. This indicates that life expectancy is independent of local tumor control. Metastatic disease, the leading cause of death, is usually diagnosed many years later, despite successful treatment of the primary tumor, and at a late stage, when no effective therapy is available. These observations suggest that the disease was already disseminated at the time of tumor diagnosis. The detection of circulating malignant cells in the bloodstream of patients at different time points in the course of the disease supports this observation. Tumor dormancy has been considered as the leading theory for this intriguing delayed appearance of metastasis. Recent knowledge gained about the biological behavior of uveal melanoma as well as novel potential therapeutic targets are presented in this review.
Henry C. Witelson Ophthalmic Pathology Laboratory and Registry, Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada. paula.blanco@mail.mcgill.ca
Paula L
PL
Blanco
Li Anne
LA
Lim
Cristina
C
Miyamoto
Miguel N
MN
Burnier
D000818:Animals; D018450:Disease Progression; D055088:Early Detection of Cancer; D023381:Endpoint Determination; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008545:Melanoma / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D014604:Uveal Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D000098943:Uveal Melanoma